Author

J. M. Lizcano

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

E. Colas· 2 shared I. Bolinaga-Ayala· 2 shared M. Vinas-Casas· 2 shared S. Espinosa-Gil· 2 shared A. Gamez-Garcia· 1 shared A. Zorzano· 1 shared B. Villafranca-Magdalena· 1 shared E. Alari-Pahissa· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Colas

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma

G. O. Gallo-Oller, G. Pons, J. Sansa-Girona, N. Navarro, P. Zarzosa, L. Garcia-Gilabert, P. Cabre Fernandez, G. Guillen Barrieza, L. Valero-Arrese, M. F. Segura, J. M. Lizcano, J. Sanchez de Toledo, L. Moreno, S. Gallego, J. Roma

This study shows TRIB3 silencing reduces Akt pathway activity and PAX3-FOXO1 levels in high-risk rhabdomyosarcoma, leading to decreased tumor growth and improved survival.

bioRxiv · Dec 1, 2023Cancer Biology

MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists and Natural Killer cells

S. Espinosa-Gil, S. Ivanova, E. Alari-Pahissa, M. Denizli, B. Villafranca-Magdalena, M. Vinas-Casas, I. Bolinaga-Ayala, A. Gamez-Garcia, E. Colas, M. Lopez-Botet, A. Zorzano, J. M. Lizcano

This study identifies ERK5 as a regulator of cancer cell resistance to TRAIL-induced apoptosis, showing that ERK5 inhibition sensitizes cancer cells to TRAIL and Natural Killer cell-mediated killing.

bioRxiv · Mar 22, 2023 · PreprintCancer Biology

The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival

N. Dieguez-Martinez, S. Espinosa-Gil, G. Yoldi, E. Megias-Roda, I. Bolinaga-Ayala, M. Vinas-Casas, I. Domingo-Orti, H. Perez-Montoyo, J. R. Bayascas, E. Colas, X. Dolcet, J. M. Lizcano

This study identifies the ERK5/NF-κB pathway as a driver of endometrial cancer proliferation and survival, showing that its inhibition sensitizes tumors to chemotherapy and reduces xenograft growth.

bioRxiv · May 31, 2022Cancer Biology